BRPI0307699A2 - Tratamento de hiperplasia benigna da próstata com sarms. - Google Patents

Tratamento de hiperplasia benigna da próstata com sarms.

Info

Publication number: BRPI0307699A2
Authority: BR; Brazil
Prior art keywords: type; subject; sarm; metabolite; isomer
Prior art date: 2002-02-07

Application number

BRPI0307699-7A

Other languages

English (en)

Inventor

Mitchell S Steiner

Karen A Veverka

Duane D Miller

James T Dalton

Kiwon Chung

Wenqing Gao

Original Assignee

Gtx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-07

Filing date

2003-02-06

Publication date

2015-06-16

2003-02-06 Application filed by Gtx Inc filed Critical Gtx Inc

2015-06-16 Publication of BRPI0307699A2 publication Critical patent/BRPI0307699A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Surgical Instruments (AREA)
Percussion Or Vibration Massage (AREA)
Steroid Compounds (AREA)

BRPI0307699-7A 2002-02-07 2003-02-06 Tratamento de hiperplasia benigna da próstata com sarms. BRPI0307699A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US35430002P	2002-02-07	2002-02-07
US36299702P	2002-03-11	2002-03-11
PCT/US2003/003447 WO2003065992A2 (en)	2002-02-07	2003-02-06	Treating benign prostate hyperplasia with sarms

Publications (1)

Publication Number	Publication Date
BRPI0307699A2 true BRPI0307699A2 (pt)	2015-06-16

Family

ID=27737453

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0307699-7A BRPI0307699A2 (pt)	2002-02-07	2003-02-06	Tratamento de hiperplasia benigna da próstata com sarms.

Country Status (20)

Country	Link
US (2)	US7776921B2 (pt)
EP (1)	EP1480634B1 (pt)
JP (3)	JP4677516B2 (pt)
KR (2)	KR20100112659A (pt)
CN (2)	CN101732298B (pt)
AT (1)	ATE518537T1 (pt)
AU (2)	AU2003216174C1 (pt)
BR (1)	BRPI0307699A2 (pt)
CA (2)	CA2475108A1 (pt)
CY (1)	CY1111917T1 (pt)
DK (1)	DK1480634T3 (pt)
EA (2)	EA013399B1 (pt)
GE (1)	GEP20074122B (pt)
HR (2)	HRP20040793A2 (pt)
IL (2)	IL163380A (pt)
MX (1)	MXPA04007639A (pt)
PT (1)	PT1480634E (pt)
RS (1)	RS69704A (pt)
TW (2)	TW200918043A (pt)
WO (1)	WO2003065992A2 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7759520B2 (en)	1996-11-27	2010-07-20	University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US7518013B2 (en)	2000-08-24	2009-04-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators
US8445534B2 (en)	2000-08-24	2013-05-21	University Of Tennessee Research Foundation	Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7026500B2 (en) *	2000-08-24	2006-04-11	University Of Tennessee Research Foundation	Halogenated selective androgen receptor modulators and methods of use thereof
US7645898B2 (en)	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7919647B2 (en)	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en)	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
US20040260108A1 (en) *	2001-06-25	2004-12-23	Dalton James T.	Metabolites of selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US20060276539A1 (en) *	2002-10-16	2006-12-07	Dalton James T	Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
CA2501874A1 (en) *	2002-10-16	2004-04-29	Gtx, Inc.	Treating androgen decline in aging male (adam)-associated conditions with sarms
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
FI20030958A0 (fi)	2003-06-27	2003-06-27	Orion Corp	Uusia yhdisteitä
HRP20060036B1 (hr) *	2003-06-27	2014-04-25	Orion Corporation	Derivati propionamida koji se koriste kao modulatori androgenih receptora
CN101721402B (zh) *	2003-10-14	2013-03-13	田纳西大学研究基金会	用选择性雄激素受体调节剂治疗骨相关病症
AU2005214167B2 (en)	2004-02-13	2008-08-07	Warner-Lambert Company Llc	Androgen receptor modulators
JP2007532621A (ja) *	2004-04-13	2007-11-15	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	アンドロゲンモジュレータ
EP1740533A1 (en)	2004-04-22	2007-01-10	Warner-Lambert Company LLC	Androgen modulators
UA87854C2 (en) *	2004-06-07	2009-08-25	Мерк Энд Ко., Инк.	N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
MXPA06013958A (es) *	2004-06-07	2007-03-15	Univ Tennessee Res Foundation	Moduladores del receptor de androgenos selectivo metodos para utilizar los mismos.
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
PT2289872T (pt) *	2004-06-07	2017-11-01	Univ Tennessee Res Found	Utilizações médicas de um modulador seletivo de recetores andrógenos
US20110237664A1 (en) *	2004-06-07	2011-09-29	Dalton James T	Selective androgen receptor modulators for treating diabetes
WO2006006065A1 (en)	2004-07-08	2006-01-19	Warner-Lambert Company Llc	Androgen modulators
DE602005024274D1 (de)	2004-07-16	2010-12-02	Sunesis Pharmaceuticals Inc	Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
TW200724139A (en)	2005-05-05	2007-07-01	Warner Lambert Co	Androgen modulators
EP2008099A4 (en) *	2006-04-03	2009-12-23	Medexis S A	DETECTION OF MEMBRANE ANDROGEN RECEPTOR (MAR) ACTIVE SUBSTANCES
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
CN101528214B (zh)	2006-08-24	2013-06-05	田纳西大学研究基金会	取代的n-酰基苯胺及其使用方法
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
US20150071857A1 (en) *	2012-03-07	2015-03-12	Ligand Pharmaceuticals, Inc.	Steroid hormone and cholesterol pathways as one unified homeostatic system
EP2833944A4 (en)	2012-04-06	2016-05-25	Antares Pharma Inc	ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
PL2872482T3 (pl)	2012-07-13	2021-03-08	Oncternal Therapeutics, Inc.	Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
WO2015122858A1 (en)	2014-02-15	2015-08-20	Erdal Can Alkoçlar	A composition containing synthetic components formed for suppressing ribonucleotide reductase
HUP1400294A2 (hu)	2014-06-13	2015-12-28	Skillpharm Kft	Clopidogrel új alkalmazása
RU2019117364A (ru) *	2014-10-16	2019-08-05	ДжиТиИкс, ИНК.	Способы лечения урологических нарушений с применением селективных модуляторов андрогеновых рецепторов

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US644970A (en) *	1899-02-06	1900-03-06	Thomas Graham Donaldson	Dental flask.
US935044A (en) *	1909-01-12	1909-09-28	Lenn G Mccorry	Valve.
US935045A (en) *	1909-06-19	1909-09-28	Robert J Mckelvey	Turn-table.
GB1360001A (en)	1971-06-16	1974-07-17	Scherico Ltd	Pharmaceutical compositions comprising substituted anilides
US3875229A (en)	1972-11-24	1975-04-01	Schering Corp	Substituted carboxanilides
JPS6044294B2 (ja)	1976-04-15	1985-10-02	帝国臓器製薬株式会社	アニリド誘導体
US4139638A (en)	1976-09-23	1979-02-13	Schering Corporation	Methods for the treatment of hirsutism
DE2862100D1 (en)	1977-10-12	1983-01-05	Ici Plc	Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en)	1977-12-15	1980-03-04	Imperial Chemical Industries Limited	Amide derivatives
NZ197008A (en)	1980-05-22	1984-10-19	Ici Ltd	Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en)	1981-04-15	1982-10-22	Mitsubishi Petrochem Co Ltd	Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
LU88769I2 (fr)	1982-07-23	1996-11-05	Zeneca Ltd	Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8617653D0 (en) *	1986-07-18	1986-08-28	Ici Plc	Amide derivatives
GB8617652D0 (en)	1986-07-18	1986-08-28	Ici Plc	Acylanilide derivatives
US5162504A (en)	1988-06-03	1992-11-10	Cytogen Corporation	Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
JPH09508125A (ja)	1994-01-21	1997-08-19	セプラコー，インコーポレイテッド	光学的純正ｒ−（−）−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成
US5609849A (en)	1994-03-11	1997-03-11	The Trustees Of The University Of Pennsylvania	Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en)	1995-06-16	1997-08-12	Biophysica Inc.	Androgenic directed compositions
WO1998005962A1 (en)	1996-08-02	1998-02-12	Panvera Corporation	A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6492554B2 (en)	2000-08-24	2002-12-10	The University Of Tennessee Research Corporation	Selective androgen receptor modulators and methods of use thereof
US7205437B2 (en) *	1996-11-27	2007-04-17	University Of Tennessee Research Foundation	Selective androgen receptor modulators
US6995284B2 (en)	2000-08-24	2006-02-07	The University Of Tennessee Research Foundation	Synthesis of selective androgen receptor modulators
US20090264534A1 (en) *	1996-11-27	2009-10-22	Dalton James T	Selective androgen receptor modulators
US6071957A (en)	1996-11-27	2000-06-06	The University Of Tennessee Research Corporation	Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
JPH10182457A (ja) *	1996-12-25	1998-07-07	Yuichi Hashimoto	抗アンドロゲン剤
US6160011A (en)	1997-05-30	2000-12-12	The University Of Tennessee Research Corporation	Non-steroidal agonist compounds and their use in male hormone therapy
AU7723198A (en)	1997-06-04	1998-12-21	University Of Tennessee Research Corporation, The	Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
JPH1135558A (ja) *	1997-07-18	1999-02-09	Zeria Pharmaceut Co Ltd	３−ベンゾイルインドール誘導体及びそれらを含有する医薬
GB9919778D0 (en) *	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
JP2003511467A (ja)	1999-10-14	2003-03-25	ブリストル−マイヤーズスクイブカンパニー	アンドロゲンレセプターリガンド結合ドメインの結晶構造
US6583306B1 (en)	1999-10-19	2003-06-24	Nobex Corporation	Methods of asymmetrically synthesizing enantiomers of Casodex, its derivatives and intermediates thereof
BR0015124A (pt)	1999-10-27	2002-07-02	Nobex Corp	Método de preparação de um enanciÈmero substancialmente puro
UA74826C2 (en) *	2000-05-17	2006-02-15	Ortho Mcneil Pharm Inc	?-carboline derivatives as phosphodiesterase inhibitors
IL152719A0 (en)	2000-06-28	2003-06-24	Bristol Myers Squibb Co	Selective androgen receptor modulators and methods for their identification
GB0016877D0 (en) *	2000-07-11	2000-08-30	Astrazeneca Ab	Chemical compounds
US6998500B2 (en)	2000-08-24	2006-02-14	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en)	2000-08-24	2003-12-18	Dalton James T.	Selective androgen receptor modulators and methods of use thereof
MXPA03001632A (es)	2000-08-24	2004-09-10	Univ Tennessee Res Corp	Moduladores receptores de androgeno selectivos y metodos para usar los mismos.
US6838484B2 (en)	2000-08-24	2005-01-04	University Of Tennessee Research Foundation	Formulations comprising selective androgen receptor modulators
US20070161608A1 (en) *	2001-12-06	2007-07-12	Dalton James T	Selective androgen receptor modulators for treating muscle wasting
CA2469340A1 (en)	2001-12-06	2003-06-19	Gtx Inc.	Treating muscle wasting with selective androgen receptor modulators

2003
- 2003-02-06 KR KR1020107021280A patent/KR20100112659A/ko not_active Ceased
- 2003-02-06 CA CA002475108A patent/CA2475108A1/en not_active Abandoned
- 2003-02-06 RS YU69704A patent/RS69704A/sr unknown
- 2003-02-06 MX MXPA04007639A patent/MXPA04007639A/es active IP Right Grant
- 2003-02-06 US US10/359,270 patent/US7776921B2/en not_active Expired - Fee Related
- 2003-02-06 CA CA2689080A patent/CA2689080C/en not_active Expired - Fee Related
- 2003-02-06 GE GEAP8396A patent/GEP20074122B/en unknown
- 2003-02-06 HR HR20040793A patent/HRP20040793A2/xx not_active Application Discontinuation
- 2003-02-06 AT AT03737647T patent/ATE518537T1/de active
- 2003-02-06 EA EA200401043A patent/EA013399B1/ru not_active IP Right Cessation
- 2003-02-06 BR BRPI0307699-7A patent/BRPI0307699A2/pt not_active IP Right Cessation
- 2003-02-06 WO PCT/US2003/003447 patent/WO2003065992A2/en not_active Ceased
- 2003-02-06 PT PT03737647T patent/PT1480634E/pt unknown
- 2003-02-06 KR KR1020047012236A patent/KR101032661B1/ko not_active Expired - Fee Related
- 2003-02-06 JP JP2003565418A patent/JP4677516B2/ja not_active Expired - Fee Related
- 2003-02-06 DK DK03737647.2T patent/DK1480634T3/da active
- 2003-02-06 CN CN2009101619003A patent/CN101732298B/zh not_active Expired - Fee Related
- 2003-02-06 HR HR20100067A patent/HRP20100067A2/hr not_active Application Discontinuation
- 2003-02-06 EA EA200901492A patent/EA200901492A1/ru unknown
- 2003-02-06 CN CN038078007A patent/CN1646115B/zh not_active Expired - Fee Related
- 2003-02-06 AU AU2003216174A patent/AU2003216174C1/en not_active Ceased
- 2003-02-06 EP EP03737647A patent/EP1480634B1/en not_active Expired - Lifetime
- 2003-02-07 TW TW097147185A patent/TW200918043A/zh unknown
- 2003-02-07 TW TW092102512A patent/TWI374737B/zh not_active IP Right Cessation
2004
- 2004-08-05 IL IL163380A patent/IL163380A/en not_active IP Right Cessation
2009
- 2009-03-18 AU AU2009201084A patent/AU2009201084A1/en not_active Abandoned
- 2009-12-10 IL IL202675A patent/IL202675A/en not_active IP Right Cessation
2010
- 2010-05-10 JP JP2010108498A patent/JP2010209102A/ja not_active Ceased
- 2010-06-30 US US12/826,842 patent/US8088828B2/en not_active Expired - Fee Related
2011
- 2011-10-31 CY CY20111101039T patent/CY1111917T1/el unknown
2013
- 2013-04-11 JP JP2013082815A patent/JP2013144713A/ja active Pending

Also Published As

Publication number	Publication date
US7776921B2 (en)	2010-08-17
EA200901492A1 (ru)	2010-08-30
EP1480634A2 (en)	2004-12-01
RS69704A (sr)	2006-12-15
AU2003216174A1 (en)	2003-09-02
KR20040089606A (ko)	2004-10-21
EA013399B1 (ru)	2010-04-30
TW200918043A (en)	2009-05-01
TWI374737B (en)	2012-10-21
KR20100112659A (ko)	2010-10-19
EP1480634A4 (en)	2008-01-16
WO2003065992A3 (en)	2004-02-26
PT1480634E (pt)	2011-10-12
KR101032661B1 (ko)	2011-05-06
EA200401043A1 (ru)	2005-06-30
HK1068103A1 (en)	2005-04-22
AU2009201084A1 (en)	2009-04-09
CA2689080C (en)	2011-07-05
WO2003065992A2 (en)	2003-08-14
TW200307537A (en)	2003-12-16
MXPA04007639A (es)	2005-07-13
JP2010209102A (ja)	2010-09-24
AU2003216174C1 (en)	2010-01-28
DK1480634T3 (da)	2011-11-14
HRP20100067A2 (hr)	2010-04-30
US20100280107A1 (en)	2010-11-04
IL202675A (en)	2011-06-30
AU2003216174B8 (en)	2009-01-15
CN101732298B (zh)	2012-09-19
GEP20074122B (en)	2007-06-11
CN1646115B (zh)	2010-06-09
CY1111917T1 (el)	2015-11-04
US20040053897A1 (en)	2004-03-18
CA2689080A1 (en)	2003-08-14
CN101732298A (zh)	2010-06-16
CN1646115A (zh)	2005-07-27
EP1480634B1 (en)	2011-08-03
JP4677516B2 (ja)	2011-04-27
US8088828B2 (en)	2012-01-03
AU2003216174B2 (en)	2008-12-18
JP2005522431A (ja)	2005-07-28
JP2013144713A (ja)	2013-07-25
HRP20040793A2 (en)	2006-10-31
ATE518537T1 (de)	2011-08-15
IL163380A (en)	2010-06-30
CA2475108A1 (en)	2003-08-14

Publication	Publication Date	Title
BRPI0307699A2 (pt)	2015-06-16	Tratamento de hiperplasia benigna da próstata com sarms.
WO2005000213A3 (en)	2006-04-13	Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO2001044247A3 (en)	2002-01-03	Agents and methods for the treatment of proliferative diseases
AU2001248701A1 (en)	2001-10-03	Inhibitors of histone deacetylase
NO20014046L (no)	2001-08-20	Gabapentinderivater for forhindring og behandling av visceral smerte
MXPA04002397A (es)	2004-12-02	Inhibidores de histona deacetilasa.
AP1498A (en)	2005-11-21	Inhibitors of impdh enzyme.
ATE357272T1 (de)	2007-04-15	Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
TW200504078A (en)	2005-02-01	Therapeutically active compounds and their use
NO20060398L (no)	2006-02-28	Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2004105757A3 (en)	2005-05-12	Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
WO2004064735A3 (en)	2004-12-16	Treatment of benign prostatic hyperplasia
NO308037B1 (no)	2000-07-10	16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat
WO2000007576A3 (en)	2000-03-30	INHIBITORS OF TYPE 3 3α-HYDROSTEROID DEHYDROGENASE
WO2004052236A3 (en)	2004-08-26	Methods and compositions for treatment of otitis media
WO2004084943A8 (en)	2004-12-23	Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2003092606A3 (en)	2004-01-08	Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2022256723A3 (en)	2023-01-05	Tgf-beta inhibitors and therapeutic use thereof
MY118986A (en)	2005-02-28	Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
WO2003090753A8 (en)	2004-11-04	Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
WO2005016327A3 (en)	2005-04-14	Treatment of sleep disorders with cholinesterase inhibitors
EA200401100A1 (ru)	2005-04-28	1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
NO20073610L (no)	2007-09-12	Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
ATE473001T1 (de)	2010-07-15	Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
WO2001044235A3 (en)	2002-01-17	Agents and methods for the treatment of proliferative diseases

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 10A, 11A E 12A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.
2017-05-23	B25B	Requested transfer of rights rejected	Owner name: GTX, INC. (US)